EpicentRx and Texas Children’s Cancer Center announce the initiation of a Phase 1 clinical trial with RRx-001 for pediatric CNS tumors. They will investigate the safety and benefit of RRx-001, plus irinotecan and temozolomide for pediatric patients with recurrent or progressive malignant solid and central nervous system tumors.